20200311 Resultats 2019 EN
Year: 2020
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001Marchand, Semmrich, Fend et al.Immuno-Oncology summitDownload the poster herePoster Presentation
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
20200303 BT-001 presentations EN
First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
20200220 PR FPI 6002.03 EN
Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
20200107 PR TG4050 FPI – EN